NEWS      WELCOME      CONTACT EMN      EMN SO      EMN TRIALS      EMN TRIAL GROUP      EMN BIOLOGY GROUP      LOGIN      MSCNET

 Updated on: Jan 9 2014

Objectives of the EMN

In order to facilitate the thematic distribution of tasks and its ongoing progress and evaluation during 2005-2010, we have established three closely connected Joint Research Areas outlined below:

 

Disease mechanisms and Pathogenesis (Area 1),
New prognostic factors and disease monitoring (Area 2) and
Therapeutics and Methodology (Area 3).

 


The close relationship between these research areas will add personal value for each network participant. Exchange of information and experience will create mutual trust and a spirit of cooperation that will improve the quality of translational research and clinical trials throughout the network and actively involve both laboratory and clinical research groups.

 

 

Putting in place the network will initiate a political process, which will drive the project forward. This will be ensured by the establishment of an organisational structure and by access to well characterised clinical material and expertise. The network will remain open due to an ongoing process of recruitment of new members and new activities.

 

 

It is expected that the network will exert political effects outside its specific area in particular in relation to the development of new drugs and their translation to the marketplace within Europe. In addition we expect to generate new technologies and to accelerate their development and marketing within the biotechnology arena.

 

 

The integration and advancements foreseen are improved impact on the productivity, excellence, practical applicability and translation into clinical care. The synergy and the overall objectives reached by the joint programme outlined in 16 work packages will be evaluated by multiple qualitative and quantitative indicators and components:

 

 

The coherent management of a research portfolio and training programme.
Strong execution of research projects evaluated by the scientific committee.

 

 

The research infrastructure, equipment, tools and technical platforms, e.g. generation of an extensive tissue bank and clinical database.
Integration of basic research including new technologies with clinicians in order to promote translation from bench to bedside, e.g. coordinate development of "chip" based diagnostic tests based on genomics, proteomics and cytomics.

 

Interactive working through electronic communication systems, e.g. to identify new therapeutic targets for drug therapy based on high-throughput technology.

 

Great extent of mutual specialisation and complementatry, e.g. by development of a strategy to organize and conduct large-scale, international clinical trials able to address therapeutic issues that cannot be solved at a national level.

 

Interactive registration of data and educational training programme through electronic communication systems.

 

Strong commitment for network participants to secure funding beyond the period.

Secr. Hans E. Johnsen | Depart. of Haematology | Aalborg University Hospital | Sdr. Skovvej 15 | DK-9000 Aalborg | Denmark | T:+45 9766 3871 | F:+45 9766 6369